<SEC-DOCUMENT>0001213900-15-003819.txt : 20150515
<SEC-HEADER>0001213900-15-003819.hdr.sgml : 20150515
<ACCEPTANCE-DATETIME>20150515141400
ACCESSION NUMBER:		0001213900-15-003819
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20150514
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150515
DATE AS OF CHANGE:		20150515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OptimizeRx Corp
		CENTRAL INDEX KEY:			0001448431
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-BUSINESS SERVICES, NEC [7389]
		IRS NUMBER:				261265381
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-53605
		FILM NUMBER:		15867855

	BUSINESS ADDRESS:	
		STREET 1:		400 WATER ST., STE. 200
		CITY:			ROCHESTER
		STATE:			MI
		ZIP:			48307
		BUSINESS PHONE:		248-651-6558

	MAIL ADDRESS:	
		STREET 1:		400 WATER ST., STE. 200
		CITY:			ROCHESTER
		STATE:			MI
		ZIP:			48307
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k051415_optimizerx.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<HR SIZE="2" NOSHADE ALIGN="CENTER" STYLE="width: 25%; color: black">

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B><BR>
<BR>
Date of Report (Date of earliest event reported): May 14, 2015<BR>
<BR>
<U>OptimizeRx Corporation</U><BR>
(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 34%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Nevada</font></td>
    <td style="width: 1%; line-height: 115%">&nbsp;</td>
    <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">000-53605</font></td>
    <td style="width: 1%; line-height: 115%">&nbsp;</td>
    <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">26-1265381</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction</font><br>
<font style="font: 10pt Times New Roman, Times, Serif">of incorporation)</font></td>
    <td style="line-height: 115%">&nbsp;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(Commission File Number)</font></td>
    <td style="line-height: 115%">&nbsp;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(I.R.S. Employer</font><br>
<font style="font: 10pt Times New Roman, Times, Serif">Identification No.)</font></td></tr>
</table>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 50%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">400 Water Street, Suite 200, Rochester, MI </font></td>
    <td style="width: 1%; line-height: 115%">&nbsp;</td>
    <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">48307</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(Address of principal executive offices)</font></td>
    <td style="line-height: 115%">&nbsp;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(Zip Code)</font></td></tr>
</table>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant&rsquo;s telephone number,
including area code: <U>248-651-6568</U></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 100%">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<hr size="2" noshade align="center" style="width: 50%; color: black">

        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Former name or former address, if changed
        since last report)</P></td></tr>
</table>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 3%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9744;</font></td>
    <td style="width: 97%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 115%">&nbsp;</td>
    <td style="line-height: 115%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9744;</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 115%">&nbsp;</td>
    <td style="line-height: 115%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9744;</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 115%">&nbsp;</td>
    <td style="line-height: 115%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9744;</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></td></tr>
</table>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
</table>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Section 8 &ndash; Other Events</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Item 8.01 Other Events</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 14, 2015, the Company held a
conference call to discuss the Company&rsquo;s first quarter earnings and other matters of business, a transcript of which is furnished
herewith as Exhibit 99.1 and is incorporated herein by reference.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The information in Item 8.01 of this
Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities
Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;) or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth
by specific reference in such a filing.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Section 9 &ndash; Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Item 9.01 Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify; background-color: rgb(204,238,255)">
<TD STYLE="width: 15pt; text-align: right">99.1</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Conference call transcript dated May 14, 2015</TD>
</TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
</table>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">2</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>OptimizeRx Corporation</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 40%; border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">/s/ Doug Baker</font></td>
    <td style="width: 60%; line-height: 115%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Doug Baker</font><br>
<font style="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer</font></td>
    <td style="line-height: 115%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 115%">&nbsp;</td>
    <td style="line-height: 115%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Date: May 15, 2015</font></td>
    <td style="line-height: 115%">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">3</P>






<HR SIZE="2" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: black">

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f8k051415ex99i_optimizerx.htm
<DESCRIPTION>OPTIMIZERX CORPORATION EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OptimizeRx
Corporation</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Earnings Conference Call</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>May 14, 2015</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Operator</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Good day, everyone, and welcome to the OptimizeRx Corporation
First Quarter 2015 Earnings Conference Call.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Following the initial discussions, there will be time
for questions from the participants in the call. Just as a reminder, today&rsquo;s conference is being recorded. A transcript will
be available for 90 days for those interested parties who want a copy, please contact Doug Baker, in our Rochester, Michigan Headquarters.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Now, for opening remarks and introductions, I would
like to turn the conference over to Mr. Doug Baker, Chief Financial Officer for OptimizeRx.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Doug Baker - Chief Financial Officer</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Thanks, Stephanie. And welcome, everybody, to the conference
call. I&rsquo;m going to start out by reading our Safe Harbor statement.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">This conference contains forward-looking statements
within the definition of Section 27A of the Securities Act of 1933 as amended and such Section 21E of the Securities Act of 1934
as amended. These forward-looking statements should not be used to make an investment decision. The words estimate, possible and
seeking and similar expressions identify forward-looking statements, which speak only as to the date the statement was made.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">The company undertakes no obligation to publicly update
or revise any forward-looking statements whether because of new information, future events or otherwise. Forward-looking statements
are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Future events and actual results could differ materially
from those set forth and contemplated by or underlying the forward-looking statements. The risks and uncertainties to which forward-looking
statements are subject that could affect our business and financial results are included in our Annual Report on Form 10-K for
the fiscal year ended December 31, 2014, which is available on our website and on the SEC website at sec.gov.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">With that out of the way, I&rsquo;m going to give some
of the financial and company highlights before turning it over to our CEO, Dave Harrell, to add some more color.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Our sales for the first quarter were $1.5 million,
a 15% increase over the same period in 2014. We also generated positive cash flow from operations of approximately $87,000 during
the quarter. Our cash balance increased and is now over $3.5 million. Our balance sheet continued to improve and our working capital
is now approximately $3.2 million.</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Excluding non-cash expenses, the first quarter of 2015
generated operating income of approximately $50,000. We are continuing to maintain our disciplined expense control and are focused
on spending only on customer facing activities.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">We initially launched our SampleMD e-coupon solution
in early April of 2015 within the Practice Fusion network and we expect to be fully integrated by the end of the second quarter.
We also have received commitments to begin running key campaigns in NextGen and anticipate a revenue impact beginning in June.
Additionally, we are actively engaging and making progress with other leading platforms to position and prioritize integration
of our services.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">As in the past, we sponsored the ePrescribe/EHR conference
held in Philadelphia in March 2015, and that generated some significant leads for our sales force. We continued to add new brands
in 2015 at both our existing customers such as AstraZeneca and Lilly, as well as at new customers. Our programs continue to prove
an outstanding return on investment for our pharmaceutical clients as verified through independent analytics firms.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">And finally, from a technical standpoint, we&rsquo;re
completing the major technical upgrades, including migration to Oracle, to allow for very robust future growth and performance.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">With that, I&rsquo;m going to turn it over Dave Harrell.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">David Harrell - Chairman and Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Hi, everybody, and thanks for taking time
this morning to listen in on our progress. As I mentioned in the past, we&rsquo;re focused on basically four key areas. And the
first is expanding pharmaceutical brands and budget. And as Doug mentioned, we&rsquo;ve been successful at that and continue to
ramp that up.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Some examples are Nexium with AstraZeneca,
Trulicity with Lilly, NovoLog Mix with Novo Nordisk, Effexor with Pfizer, Pazeo with Alcon, and Abilify, which is one of the top
five prescribed brand drugs, with Otsuka. We anticipate those programs to be fully rolling out at the end of May and June, I think,
in general. So again, I think our sales force as they outlined are making progress with both our existing clients as well as our
new clients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Additionally, we again were the lead sponsor
and host of the industry&rsquo;s largest pharmaceutical EHR conference in which we serve both as speakers with our partners&rsquo;
great healthcare as well as again made great progress and hoping those brands realize that they have to get into the Electronic
Health Record space.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Although we have had significant success in
creating this industry, keep in mind even with our growth we still have less than 20% to 25% of the current brands that are promoting
coupons. So again, we have a huge upside growth opportunity and expect to continue to leverage that and acquire more brands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The second bucket that we will always be focusing
on is expanding physician utilization within our current EHR network. And I think, we made good progress and will continue to make
even stronger progress moving forward. Some examples are Allscripts. As we outlined Allscripts PRO had initially rolled out as
an opt-in, which was proving to be a challenge. They have made commitments and have rolled out within their largest version, for
all doctors to be an opt-out.</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">And the outcome of that is we now have 50%
more of the docs using the platform as of second quarter, and are working diligently with Allscripts to look at other ways to maximize
both PRO and of most significance, their third-largest platform that has not integrated our e-coupons and that is called TouchWorks,
which serves some of the largest health systems in the country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We expect that progress to be formalized and
hopefully we&rsquo;ll be able to report some significant news in the near future, which potentially allows us to have access to
- 50 million more prescriptions. Also some examples are DrFirst. DrFirst is also working with us and we&rsquo;ve already seen a
10% increase in unique doctors utilizing the e-coupon and anticipate another 10% to 15% increase within the next 30 to 45 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Additionally, we&rsquo;re finding new ways
to leverage our technology to deliver patient savings outside of our standard automated display for print as well as electronically
sent. And this includes working with NewCrop, one of our largest platforms. And in this case, we&rsquo;re now actually sending
alerts to the both the patient via text and emails and anticipate this to be a great growth opportunity to further increase patient&rsquo;s
awareness of these available savings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">And the pharmaceutical companies are very
excited about this as well. Additionally, Quest Diagnostics Care360, we had a very successful meeting with them, and wanted to
look beyond their EHR into their other touch points, including one of the largest in the industry patient portals that Quest Diagnostics
manages. The key with Quest Diagnostics is they reach one out of every three doctors and the reality is their EHR is only one part
of that.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">So I think, again, we&rsquo;re continuing
with our existing platforms to look at new touch points in ways to deliver value to both doctors, patients, and our pharmaceutical
manufacturers. And that, of course, will have a great impact upon our continued success on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The third bucket is to expand our promotional
networks in other EHRs and platforms. As promised, Practice Fusion was completed in early April in terms of the integration and
the launch continues to roll out. We expect completion of all users to have access by the end of June, so we are very, very excited
about the opportunity of Practice Fusion and the increase on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Additionally, we&rsquo;ve received approval
to begin to promote in June some of our key programs within NextGen, which has the potential to reach upwards of 40,000 to 50,000
new doctors. We also have been very, very aggressive and continuing to have a very strong outreach with other large EHRs and patient
portal platforms. And in fact one of the recent visits to HIMSS which is the largest electronic platform industry conference, we
had very, very successful conversations and very successful follow-up, since then with vendors that have the potential to add another
200,000 to 300,000 doctors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The key is that they have so many different
priorities right now in terms of meeting federal government mandates, but every one of them sees the value that we have. Now, it&rsquo;s
just a matter of proving priority for them. Additionally, we&rsquo;re preparing to roll out within the largest hospital system
in the country, a beta test with HCA. And with that we&rsquo;ve engaged one of the largest e-prescribing electronic health records,
eClinicalWorks.</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Additionally, to support our leadership status
in the industry, we become an active member within NCPDP, which provides guidelines for e-prescribing, and practices within the
Electronic Health Records in e-prescribing industry. Dave Lester is leading this effort and again puts us continually into the
leadership position on any rules or potential recommendations that we can participate in.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Lastly, we continue to expand in the fourth
bucket our infrastructure and resources to fully support and exploit each of the above three. In doing that, we are in the process
of making a major transition in terms of our technology platform into Oracle to support our database and allow us to fully ramp
up our transactional value at a minimum of 10-fold and even beyond that. We&rsquo;re also looking at a very - some very important
and potentially key strategic partnerships that have the potential to dramatically accelerate our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">So in conclusion, our business continues to
grow and we anticipate major acceleration upon the promotion of our programs once it&rsquo;s complete in Practice Fusion and within
NextGen, as well as other major platforms that we&rsquo;re engaged with, that we hope to close within the second-half of the year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Furthermore, although our current business
is already generating cash, as we begin to accelerate our high gross margin combined with our low fixed cost continues to provide
a highly leveraged business that will generate significant profits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">So at this time, we&rsquo;d like to turn it
over to any questions.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Question and Answer Session</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt"><B>Operator</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Your first question comes from the line of Harvey Poppel
with Poptech, LP.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Harvey Poppel - Poptech, LP</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Hi, Dave, and hi, Doug. Congratulations on the first
quarter, sounds like again a lot of progress in your various, what you call buckets. Couple of questions on the - one on the balance
sheet here, I noticed deferred revenue went up, considerably almost doubled, what is that all about, as for $130,000 ?</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Doug Baker - Chief Financial Officer</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">So what happens is, sometimes pharmaceutical companies
want to pay for things in advance, because they&rsquo;re getting to an end of a budget year that sort of thing. So that&rsquo;s
what it relates to.</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Harvey Poppel - Poptech, LP</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Okay, fine. And then I also noticed you paid off your
revenue share. You paid off more than you&rsquo;ve paid off in the past, that number payables came down quite a bit?</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Doug Baker - Chief Financial Officer</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Also - as the number gets higher there is a little
bit of seasonality, so there were a lot of things that happened in the fourth quarter, they get paid in the first quarter, so over
time that evens out.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Harvey Poppel - Poptech, LP</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Right. And then on the - your litigation with LDM,
which is mentioned in the 10-Q, are you - LDM and PDR, are you still paying these guys while you&rsquo;re in litigation, or do
you suspend the payment?</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Harrell - Chairman and Chief Executive Officer</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">We continue to pay them to be in compliance, but that
issue is being brought up as well. So, again, we expect very favorable resolution to this matter and, again, anticipate that the
partnership remains a great driver opportunity of our revenue.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Harvey Poppel - Poptech, LP</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Okay. Looking forward, can you give us any sense, you
- in the Q you mentioned very specifically that you expect to be profitable going forward, is that GAAP profitability?</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Doug Baker - Chief Financial Officer</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Yes. As our revenues grow, as we can see we&rsquo;re
close this quarter. As our revenue grows we should reach GAAP profitability. And with that we probably ought to move on to the
next question, if you want to hop back in line, Harvey, that&rsquo;d be good.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Harvey Poppel - Poptech, LP</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Okay. Thank you.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Harrell - Chairman and Chief Executive Officer</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Thank you.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt"><B>Operator</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Your next question comes from the line of Brian Murphy
with Merriman Capital.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Brian Murphy - Merriman Capital Research</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Hi, thanks for taking my question. And I don&rsquo;t
know whether this is for Doug or Dave. But could you help us maybe understand or help us what to expect in terms of normal seasonality
from December to March. So in this quarter just, for example, I mean, how much of that delta there is normal seasonality and how
much would be due to some kind of one-time timing issues with programs, et cetera?</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Harrell - Chairman and Chief Executive Officer</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Yes. Unfortunately, and again it&rsquo;s been continually
you see a dip in revenue within first quarter, because the budgets are never finalized and the assets and the programs are never
completely approved by the pharmaceutical company. So you see some delay in terms of when we can start launch those. Over time,
I - perhaps that can change, we do our best to avoid that. But again we&rsquo;re - these are multibillion-dollar companies that
have very slow processes and final - finalities in terms of getting the budgets formally approved in the programs and information
that we require into our system.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Brian Murphy - Merriman Capital Research</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Okay, great. That&rsquo;s helpful. And Dave, just as
a follow-up, I guess, you touched on a lot of things that you have in the pipeline, and you guys just seem to have a number of
different levers that you can pull to accelerate revenue growth here. So just looking at March quarter results, you get revenue
growth of 15%, just given everything that you&rsquo;ve got in the pipeline and your opportunities to sort of accelerate the momentum
of the business, how should we think about the revenue growth profile of the business, just in general?</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Harrell - Chairman and Chief Executive Officer</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Well, again, at the end of the day we have a saying
that, we never have bad meetings. There&rsquo;s never an EHR that we talk to and says, listen, your doctors want this, this is
the value, period.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">The second thing is they can drive significant revenue
that falls directly to their bottom line. The reality is, when can they get the time to integrate our solutions, that&rsquo;s the
key thing. So, there are so many mandates on these EHRs that, it&rsquo;s just a matter of getting priority, so we&rsquo;re looking
at different strategies with that, and we continue to outline the value to it, and again, we get terrific reception.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">So the key is to really, number one, get the full rollouts
once we get the commitments and complete the integration, number one. And number two, from there, engage these companies at the
highest levels of the organization that we can get to, to show, listen, this is good for your current business of serving doctors
and it&rsquo;s good for your bottom line as well. And I think we&rsquo;re getting closer and closer where some of these EHRs that
we&rsquo;ve engaged over a year or even two years are finally saying yes. We know that we need this. So, again, the potential is
enormous, and sometimes the timing of it is frustrating in a way, because the integration might take two to three weeks frankly.
But again, there are so many things of where that fits into the Queue.</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">The second thing is, pharmaceutical companies too -
it&rsquo;s - we use a term that is it almost marketing malpractice that you&rsquo;re not integrating your patient support in terms
of the EHRs that&rsquo;s what doctors want it. It&rsquo;s most effectively influencing value decisions of, in prescribing decisions,
and it&rsquo;s the best way to increase adherence for patient&rsquo;s plans. So, again, as we sponsor these type of conferences,
we really got to sense that the market is now already for the players that have an engaged, at least, test the waters.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">So, again, we&rsquo;ve made tremendous strides in building
a new industry in a huge and highly regulated industry. But our sense is that the industry is finally saying, this is an innovative
strategy, this is a 101 strategy that we have to start doing. So, again, the timing it has - it seems like it&rsquo;s right there,
but again, in these highly regulated industries on the pharma side and the secondary side of these organizations that have so much
mandates from the government.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Again, unfortunately, we aren&rsquo;t always the first
or second priority, but we are a priority. So our job is to make sure that we leverage that and get these more pharma brands in,
because it doesn&rsquo;t make sense why they are not, and the EHRs to say, hey, this is important. Sorry for the long-winded answer,
but&hellip;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Brian Murphy - Merriman Capital Research</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">No, I appreciate - I appreciate all the color, Dave.
Thanks very much. I&rsquo;ll hop back in the queue.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt"><B>Operator</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Your next question comes from Joey Delahousse, a private
investor.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Joey Delahousse</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Yes. Hi, thanks for taking the call. David, I&rsquo;d
just like some clarification on the PDR and LDM litigation, I saw in the 10-Q that you, I guess, re-filed to condense the two suits
into one here in early May. What is your expectation for timing for how this suit sort of plays out and when, I guess, we&rsquo;ll
get some sort of definitive answer one way or another?</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Harrell - Chairman and Chief Executive Officer</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Yes, that&rsquo;s a little bit beyond my grasp. I mean,
we&rsquo;re just entering it. But our hope is that this will be amicably settled. The reality is we&rsquo;ve entered into a relationship
that was to be mutually beneficial for both parties in it, up to this point has not been for us. And, again, there are commitments
on both sides and we aim to have those commitments mutually satisfied, and if that&rsquo;s the case, it will be beneficial for
both parties. So, again, we&rsquo;re in early stages of this, and we do anticipate favorable outcomes. But I can&rsquo;t give you
much timing on that, it&rsquo;s really out of my expertise.</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Joey Delahousse</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Yes. Is PDR essentially so far, at least, looking to
replace the prescription service that you guys provide with LDM provides?</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Harrell - Chairman and Chief Executive Officer</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Well, again, they offer a variety of different services
that are why we entered the agreement synergistic with our services. And that was always anticipated their view as well, which
is why we signed the agreement. So we can&rsquo;t speak to what their motives are. We can only speak to that. We have expectations
and the commitments that we&rsquo;ve given are being honored and we expect the same on their end.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Joey Delahousse</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Okay. If I recall, the PDR integration and what LD
results bring to the table, that was a pretty significant sort of a growth catalyst for this year, and we&rsquo;d like to see that
continuing to be the case. I just wonder if you&rsquo;re in litigation with someone and they are much bigger than you and that
they have partnered with someone else. Is that kind of a realistic outcome and they seem if it wasn&rsquo;t but any comments with
regard to&hellip;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Harrell - Chairman and Chief Executive Officer</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Yes. Again, I think we have our agreement from our
viewpoint is very clear, and the obligations on both parties should represent significant benefits in terms of revenue and profits
to both sides. And we anticipate enforcing that, and again, there is a lot of benefits to both organizations, which is why the
agreement was signed. So we want to make sure it&rsquo;s mutual, and we have every intention of making that happen.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Joey Delahousse</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Yes, okay. Okay, that&rsquo;s all I have for now.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Harrell - Chairman and Chief Executive Officer</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Thank you.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Joey Delahousse</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Let me hop back in.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt"><B>Operator</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Your next question comes from the line of Gregg Hillman
with First Wilshire Securities.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Gregg Hillman - First Wilshire Securities</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Yes, good morning, gentlemen.</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Harrell - Chairman and Chief Executive Officer</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Good morning.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Gregg Hillman - First Wilshire Securities</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Yes, Dave, on the whole question of your constraints
for growth, for your company, you just mentioned EHR and you are interfacing with these people. And have you wind up all your drugs
in case we get a big, a lot of people would do want to integrate that you have enough technical people at your end or people that
you can contract out with that you can fulfill that integration?</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Harrell - Chairman and Chief Executive Officer</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Yes, very good question. The answer is yes. I mean,
at the end of the day our processes, I mean, we&rsquo;ve integrated in multiple platforms very seamlessly. We understand exactly
what it takes, and it&rsquo;s generally a plug-and-play system from our end. They use the same API web services, the same processes.
And so from our end, we absolutely can support it.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Now, if we happen to have three, four, or five, we
certainly can. We do have an outsourced company that&rsquo;s an expert in our business as well. So we do have the resources available.
And, again, that would be a great problem to have, and one that we wouldn&rsquo;t say is unrealistic. There&rsquo;s again the level
of multiple people that are interested in our technology is amazing. So it just needs to happen on timing that&rsquo;s unfortunately
out of our control.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Gregg Hillman - First Wilshire Securities</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Okay. And the question, so your key marketing effort
is oriented to signing up the EHRs for big health systems, is that correct? Not for pharma, the EHRs are more important than pharma,
correct?</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Harrell - Chairman and Chief Executive Officer</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">No, I would say, so at the end of the day, we have
20% of the market in pharma. So we have a huge upside in pharma and we have probably the same 20% of the market in the EHRs in
terms of active use right now. That&rsquo;s going to change once Practice Fusion fully gets launched and we have access to NextGen,
but again, there is huge growth on both upsides.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">So that we serve, our marketing efforts are centered
on both and they are equally important. If we accelerate one, have a major impact; if we celebrate or - excuse me, accelerate another,
it will be twofold in terms of that. So it&rsquo;s a pretty simple business model. You either grow your business from more brands.
The transactions are more doctors using your existing brands. Ideally, we&rsquo;re - our marketing efforts starts to do both.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Gregg Hillman - First Wilshire Securities</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Okay. All right. Thanks very much.</P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Harrell - Chairman and Chief Executive Officer</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Thank you.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt"><B>Operator</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">At this time we have reached the allotted time for
questions. Your final question comes from Ron Chez , private investor.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Ron Chez</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Good morning.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Harrell - Chairman and Chief Executive Officer</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Good morning.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Ron Chez</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Hello. You - I had a question about sales growth, and
I understand why you can&rsquo;t be specific about that, do you want to speak to the opportunity in terms of the internal goals
that you&rsquo;ve established for the company, what kind of goals?</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Harrell - Chairman and Chief Executive Officer</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Yes, I mean, we are not giving any guidance, because
there are so many factors that are out of our control right now. We know that the opportunity is huge, the timing is always an
issue. But clearly, we&rsquo;re in line with our expectations for second quarter and again are equally and very excited about the
opportunities to capture even a small percentage of what we have on our play as we sit here talking to you today that all have
huge opportunities accelerate our growth. So beyond that, Ron, again, we can&rsquo;t give much color based on those aspects.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Ron Chez</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">indiscernible.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Harrell - Chairman and Chief Executive Officer</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Yes, very, very excited about the business. Again,
the reality is timing of these large institutions and platforms that we&rsquo;re dealing with is not always certainly in line with
what we want, but the reality is we do have the infrastructure in place. We have the right solution in place, both the pharmaceutical
companies, who we&rsquo;ve proven value in ROI. And the EHRs know that they have to bring additional value to their doctors, number
one, and they also know that they need incremental profits because it&rsquo;s becoming a very somewhat of a commodity industry
in terms of the standard delivery.</P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">So their ability to bring value and that will really
help the patient improve their outcomes as well as be paid for that value in unique ways, ideally through the pharmaceutical company
by plugging their technology, will become even more important.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Ron Chez</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">And if you could, as you grow - hopefully grow the
business, what kind of expectation plus or minus in some kind of range would you look towards with regard to gross margin and operating
income as a percentage of sales, if you would.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Harrell - Chairman and Chief Executive Officer</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Yes, I mean, at the end of the day, this can accelerate
really quickly. And just to use a hypothetical, I mean our business is so highly leveraged the more we grow our top line. For example,
at that point when we get to $20 million revenues, that actually provides bottom line profits of about $5.5 million. I think, Doug,
you&rsquo;d confirm that and it continues to accelerate and become even greater as you grow from $20 million to $30 million to
$40 million.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">So again, we know we&rsquo;re in the right business.
We know that it&rsquo;s highly, highly leveraged. The reality is we just have to keep working to get these platforms to commit
to us and expand. And number two, we need the pharma companies that have been slow to realize that this isn&rsquo;t innovation
anymore; this is a requirement of standardized promotional practice. And I think we&rsquo;re getting very, very close to each and
we continue to make progress. But I hope that that will continue to accelerate.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Ron Chez</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Thank you.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Harrell - Chairman and Chief Executive Officer</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Sure. And by the way, I shouldn&rsquo;t say, hope.
I am confident. So I think that, again, we got the right marketing plan for the EHRs. We&rsquo;ve got the right sales groups. We&rsquo;re
expanding our sales force as well in second quarter. And again, we are committed to never letting resources be an inhibitor towards
our progress. We do - we&rsquo;re in a good financial position to support customer facing initiatives. And again, overall, remain
very excited about what we have laid out, our pipeline and what we expect moving forward in 2015 and beyond. So thank you, everybody.
And again, we really appreciate everybody taking the time.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt"><B>Operator</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Thank you. This concludes today&rsquo;s conference.
You may now disconnect.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt">11<DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
